A graphic featuring the FDA logo with text that reads "FDA APPROVES Opdivo + Yervoy MSI-H Colorectal Cancer 79% RISK REDUCTION." The background shows a person in a white lab coat in a laboratory setting.

FDA Approves Opdivo / Nivolumab Plus Yervoy / Ipilimumab for MSI-H/dMMR Colorectal Cancer: A Precision Oncology Milestone

Date: April 8, 2025 On April 8, 2025, the FDA granted regular approval to nivolumab (Opdivo) combined with ipilimumab (Yervoy) for first-line treatment of unresectable or metastatic MSI-H or dMMR colorectal cancer in adults and pediatric patients aged 12 and older. This landmark decision, grounded in the CHECKMATE-8HW trial, positions dual checkpoint inhibition as a … Continue reading FDA Approves Opdivo / Nivolumab Plus Yervoy / Ipilimumab for MSI-H/dMMR Colorectal Cancer: A Precision Oncology Milestone

OncologyTube